1.Design of a ECG Telemonitoring System in Dual Processor Based on 3G
Li SONG ; Qingjian MENG ; Guangyu ZHANG ; Daiqing ZHAI ; Weifang CAO
Chinese Journal of Medical Physics 2010;27(2):1758-1761
Objective: This paper proposes a design of portable ECG monitor in dual processor based on 3G, analyzes the design for function module. Methods: Bases on 3G, network, multimedia technology, the monitor equips an TMS302VC5402 micro-processor as its main controller, digital signals processor BSP15 process multimedia message,and 3G communication module HC25 to realize the wireless communication. Results: The system has the functions of ECG display and automated analysis and diagnosis, which can detect and send the data to monitoring center of hospital within the coverage of 3G network.The system can help a patient far away from the hospital save herself(or himself) by the two-way video technology. Conclusions: The real-ization of this system can help doctor real-time, full-scale, no the region restrainedly to obtain the ECG message of patient. The system is suitable for the patient of coronary.The 3G leads the ECG information to deliver more rapidly and conveniently.
2.Tangential excision and dermabrasion in treatment of superficial giant congenital melanocytic nevus
Yu YANG ; Qingjian ZHENG ; Li DING ; Shengwu ZHENG ; Genhui LIN
Chinese Journal of Medical Aesthetics and Cosmetology 2011;17(6):423-425
ObjectivePresent treatment in plastic surgery on giant congenital melanocytic nevus has always been a tough practice because it is difficult to achieve balance between effects and costs of treatment.This paper aimed to explore the concrete procedure of tangential excision and dermabrasion in treatment of adult giant congenital melanocytic nevus. Methods Taking into consideration pathological examination results before surgery,diseased regions,psychological expectancy and other factors,we used a humby knife or globe grinding head to remove giant congenital relanocytic nevus by wiping off the surface of it in 10 cases.After operation,the operated area of the skin underwent a process of healing in a moisturized state.In each case,surgical procedure was carried out by 1 2 sta ges,with the interval period ranges from 3 months to 6 months.ResultsOne to 3 years follow-ups showed that among those cases,5 cases obtained good results in which skin color of surgical area turned to normal and pathological examination showed that nevus cells disappeared,4 cases achieved improvement,and 1 case was relapsed.ConclusionsThe two alternative methods for treatment of giant congenital melanocytic nevus,either tangential excision or dermabrasion,with combination of pathological examination results,diseased regions,and psychological expectancy should be taken into consideration,which can remain a maximum balance between effects and costs of treatments.Tangential excision and dermabrasion are effective in some cases of giant congenital nevus where traditional methods do not work,or in order to reduce the cost of body appearance in treatment.Therefore,these two methods deserve to be adopted extensively in clinical therapy.But it still needs further accumulation of experience in practice and longer period of follow-up after operation.
3.Simultaneous Determination of Four Components in Huangqi Shengmai Decoction by HPLC-DAD
Cheng LU ; Shenghui ZHOU ; Wei LI ; Xiuli ZHENG ; Qingjian GAO ; Hao TANG
Chinese Journal of Information on Traditional Chinese Medicine 2015;(7):96-99
Objective To establish a method for simultaneous determination of contents of schisandrin B, schisantherin A, lobetyolin and ruscogenin in Huangqi Shengmai Decoction with HPLC method. Methods The chromatographic column was an Agilent Eclipse C18 column (4.6 mm × 250 mm, 5 μm) that was maintained at a constant temperature of 30 ℃. The mobile phase was 0.1% acetic acid solution-acetonitrile, with gradient elution. The flow rate was 1.0 mL/min. The detection was at wavelength of 280 nm. Results The standard curves of schisandrin B, schisantherin A, lobetyolin and ruscogenin had good linearity in the ranges of 0.862 5-21.562 5μg (r 2=0.999 1), 0.737 5-18.437 5μg (r 2=0.999 4), 0.095 2-2.380 0 μg (r 2=0.999 6), and 0.810 0-20.250 0 μg (r 2=0.999 0), respectively. The average recoveries of the four components were 98.06%(RSD=1.64%), 99.61%(RSD=2.72%), 97.98%(RSD=1.45%), and 99.30%(RSD=1.25%), respectively. Conclusion This method is accurate, rapid and specific, achieving the stable results with high reproducibility.
4.Study on the relationship between type 2 diabetes peripheral neuropathy and the activity of serum superoxide dismutase
Ni GUO ; Weimin WANG ; Xin YAN ; Qingjian SU ; Meijuan WEI ; Li YANG
International Journal of Laboratory Medicine 2014;(18):2453-2454,2456
Objective To study the relationship between type 2 diabetes peripheral neuropathy and the activity of serum super-oxide dismutase(SOD) ,and the relationship between the activity of serum SOD and gender ,age ,and blood glucose concentrations in patients with type 2 diabetes peripheral neuropathy .Methods One hundred and twenty-five T2DM patients with diabetic peripheral neuropathy(DPN) and 125 healthy individuals were enrolled in the study .The pyrogallol autoxidation method were used to deter-mine the the activity of serum SOD ,and then the differences of serum SOD activity were compared between the 2 group of people . The relationship between the activity of serum SOD and gender ,age ,and blood glucose concentrations in patients with type 2 diabe-tes peripheral neuropathy were analyzed .Results The difference of the activity of serum SOD between type 2 diabetes peripheral neuropathy group and control group was statistically significant (t=7 .798 ,P=0 .000) .There were no differences between the ac-tivity of serum SOD and gender ,age ,and blood glucose concentrations in patients with type 2 diabetes peripheral neuropathy .The SOD activities in 6 .1-7 .0 mmol/L and ≥7 .0 mmol/L groups were statistically significant (P=0 .034) .Conclusion The activity of serum SOD increase in T2DM patients with DPN .The activity of serum SOD is associated with blood glucose concentrations ,and might increase with elevated blood glucose .
5.Application of flexible ambrosia for body weight control among youths
Wenjing GONG ; Qingjian HUANG ; Dawen GAO ; Wubin QU ; Zhihui LI ; Yiming LU ; Yan GAO ; Peijin LI ; Chenggang ZHANG
Military Medical Sciences 2016;40(8):651-656
Objective To evaluate whether flexible ambrosia,by which people can take special prebiotics instead of dining to alleviate their sense of hunger is a healthy, safe and effective weight loss method by analyzing the effects of flexible ambrosia on body weight, body composition, physiological and chemical indexes of young volunteers.Methods Young volunteers were tested on flexible ambrosia for seven days using special prebiotics instead of normal food.Body weight, waist circumference, body composition and blood biochemical indexes ( blood pressure, blood glucose, liver function, renal function, blood electrolyte, and blood lipid ) were measured and recorded before and after the test respectively.The volunteers′subjective feelings ( hunger, energy, fatigue, etc) were recorded during the test every day by way of e-form records.Results All volunteers of the flexible ambrosia test reduced their body weight, body mass index (BMI), waist circumference, visceral fat index (VAI) and body fat rate (Fat,%)significantly (P<0.01)in seven days, while the body water rate, muscle mass, body protein and bone did not significantly change or rise.There was no significant functional abnormity of the liver kidney, or blood electrolytes and blood lipid.All volunteers were in good physical condition, high-spirited and slept well, high quality sleep, without any obvious hunger and fatigue response in seven days.Conclusion Flexible ambrosia seems to be a healthy, safe and effective method, and provides an important scientific basis and reference for weight loss in the military.
6.Recent advance in new strategies for therapeutic peptide delivery to the central nervous system
Qingjian WU ; Shuyin SUN ; Houwen CHENG ; Zifei LI ; Rongxia XIE ; Baoliang SUN
Chinese Journal of Neuromedicine 2019;18(7):736-739
With the rapid development of biotechnology, therapeutic peptide has been a hot area in the central nervous system drugs due to its features of easy to design and target specificity. However, therapeutic peptide is difficult to cross the blood brain barrier into the central nervous system and target cells, coupled with its in vivo instability, which seriously restricts its application in central nervous system diseases. This review focuses on the progress of therapeutic peptides across the blood brain barrier targeting the central nervous system, compares and analyses the methods of increasing therapeutic peptides penetration, specificity and stability in combination with other molecules, in order to provide help for the development of central nervous system drugs.
7.Preventive and therapeutic effects of compound wild chrysanthemum eye pad on blue light-induced alteration of meibomian gland function in mice and its mechanism
Yong LI ; Caihong HUANG ; Qingjian LI ; Yuqian WANG ; Yufei LYU ; Zhaoqiang ZHANG ; Jiaoyue HU ; Zuguo LIU
Chinese Journal of Experimental Ophthalmology 2024;42(2):117-128
Objective:To investigate the preventive and therapeutic effects of compound wild chrysanthemum eye pad on blue light-induced alteration of meibomian gland function in mice and its mechanism.Methods:Sixty-four 15-week-old male C57BL/6J mice were divided into two groups of 32 mice each according to random numbers for the prevention test and the treatment test.The respective 32 mice in the prevention and treatment experiments were randomly divided into normal group, blue light group, solvent group and eye pad group according to random numbers, with eight mice in each group, respectively.In the prevention experiments, mice in each group were exposed to blue light at a wavelength of 460 nm and a light intensity of 2 000 lx for 6 hours per day for 15 consecutive days to establish a mouse model of meibomian gland function changes except for the normal group.The solvent group and the eye pad group were treated with the corresponding eye pad before and after the blue light exposure for 25 minutes daily for the 15 consecutive days.The blue light group was treated with blue light exposure only for 15 days, and the mice were photographed at the edge of the meibomian gland on day 15 to observe the function of the meibomian gland except for the normal group.In the treatment test, all groups of mice except the normal group were induced the altered function of the mouse meibomian gland by the above method.The solvent and eye pad groups were treated with corresponding eye pads for 25 minutes in the morning and afternoon of each day for 15 consecutive days after blue light exposure.The blue light group was kept in a standard environment for 15 days and the changes in meibomian gland function of mice were detected by meibomian gland photographs on day 15.Photography of the eyelid margin in vitro, oil red O staining, and hematoxylin-eosin staining were performed to observe the histologic changes in the meibomian glands of mice after the preventive and experimental treatment.The relative expression of interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) mRNA in mouse meibomian gland tissues was detected by real-time fluorescence quantitative PCR.The expression of nuclear factor-κB (NF-κB) and phosphorylation of NF-κB (p-NF-κB) proteins in mice meibomian gland tissues was detected by Western blot to assess the degree of amelioration of blue light-induced inflammation in mouse meibomian glands by the compound wild chrysanthemum eye pad.This study was conducted in accordance with the Statement of the Association for Research in Vision and Ophthalmology on the Use of Animals in Ophthalmology and Vision Research, and was approved by the Animal Ethics Committee of Xiamen University (No.XMULAC20220258). Results:Compared with the normal group, a gradually increased number of blocked meibomian gland openings, and a gradually decreased remaining area of lower meibomian gland, were observed in the mice after 15 days of blue light group, and all the differences were statistically different (all at P<0.05). In the prevention test, the number of obstructed opening in the eye pad group was 1.833±0.753, which was significantly less than 3.667±1.033 in the solvent group ( P<0.05). The relative remaining area of the lower lid meibomian gland in the eye pad group was 0.718±0.091, which was significantly greater than 0.624±0.130 in the solvent group ( P<0.05). Hematoxylin-eosin staining showed inflammatory cell infiltration in mouse meibomian gland in the blue light and solvent groups.There was no inflammatory cell infiltration in eye pad group, and the morphology of the acini was similar to that of the normal group.Oil red O staining showed that there was no significant lipid deposition in the groups.The relative expressions of IL-1β, IL-6, TNF-α, and IFN-γ mRNA were significantly lower, and the relative expressions of NF-κB and p-NF-κB proteins were significantly lower in the eye pad group than in the solvent group, showing statistically significant differences (all at P<0.05). In the treatment test, the number of obstructed openings in the eye pad group and solvent group was 4.333±1.211 and 4.833±1.722, respectively, and the relative remaining area of the lower meibomian gland was 0.572±0.151 and 0.588±0.154, respectively, showing no statistically significant differences (both at P>0.05). Hematoxylin-eosin staining showed inflammatory cell infiltration in mouse meibomian glands in the blue light and solvent groups, with a similar morphology of acini as in the normal group.There was no inflammatory cell infiltration in eye pad group.Oil red O staining showed that there was no significant lipid deposition in the groups.The relative expressions of IL-1β, IL-6, and IFN-γ mRNA were significantly lower and the relative expressions of NF-κB and p-NF-κB proteins were significantly lower in the eye pad group than in the solvent group (all at P<0.05). Conclusions:Compound wild chrysanthemum eye pad may have preventive and therapeutic effects on blue light-induced changes in meibomian gland function by reducing the inflammatory response of meibomian gland tissue through the inhibition of the NF-κB signaling pathway.
8.Rapamycin mediated caspase 9 homodimerization to safeguard human pluripotent stem cell therapy.
Yang YANG ; Yang LIU ; Min CHEN ; Shuangpeng LI ; Xuan LU ; Yu HE ; Kun ZHANG ; Qingjian ZOU
Chinese Journal of Biotechnology 2023;39(10):4098-4107
Human induced pluripotent stem cells (hiPSCs) are promising in regenerative medicine. However, the pluripotent stem cells (PSCs) may form clumps of cancerous tissue, which is a major safety concern in PSCs therapies. Rapamycin is a safe and widely used immunosuppressive pharmaceutical that acts through heterodimerization of the FKBP12 and FRB fragment. Here, we aimed to insert a rapamycin inducible caspase 9 (riC9) gene in a safe harbor AAVS1 site to safeguard hiPSCs therapy by drug induced homodimerization. The donor vector containing an EF1α promoter, a FRB-FKBP-Caspase 9 (CARD domain) fusion protein and a puromycin resistant gene was constructed and co-transfected with sgRNA/Cas9 vector into hiPSCs. After one to two weeks screening with puromycin, single clones were collected for genotype and phenotype analysis. Finally, rapamycin was used to induce the homodimerization of caspase 9 to activate the apoptosis of the engineered cells. After transfection of hiPSCs followed by puromycin screening, five cell clones were collected. Genome amplification and sequencing showed that the donor DNA has been precisely knocked out at the endogenous AAVS1 site. The engineered hiPSCs showed normal pluripotency and proliferative capacity. Rapamycin induced caspase 9 activation, which led to the apoptosis of all engineered hiPSCs and its differentiated cells with different sensitivity to drugs. In conclusion, we generated a rapamycin-controllable hiPSCs survival by homodimerization of caspase 9 to turn on cell apoptosis. It provides a new strategy to guarantee the safety of the hiPSCs therapy.
Humans
;
Induced Pluripotent Stem Cells
;
Sirolimus/metabolism*
;
Caspase 9/metabolism*
;
RNA, Guide, CRISPR-Cas Systems
;
Pluripotent Stem Cells/metabolism*
;
Cell Differentiation
;
Puromycin/metabolism*